TY - JOUR
T1 - The nucleus accumbens
T2 - Mechanisms of addiction across drug classes reflect the importance of glutamate homeostasis
AU - Scofield, M. D.
AU - Heinsbroek, J. A.
AU - Gipson, C. D.
AU - Kupchik, Y. M.
AU - Spencer, S.
AU - Smith, A. C.W.
AU - Roberts-Wolfe, D.
AU - Kalivas, P. W.
N1 - Publisher Copyright:
© 2016 by The American Society for Pharmacology and Experimental Therapeutics.
PY - 2016/7
Y1 - 2016/7
N2 - The nucleus accumbens is a major input structure of the basal ganglia and integrates information from cortical and limbic structures to mediate goaldirected behaviors. Chronic exposure to several classes of drugs of abuse disrupts plasticity in this region, allowing drug-associated cues to engender a pathologic motivation for drug seeking.Anumber of alterations in glutamatergic transmission occur within the nucleus accumbens after withdrawal from chronic drug exposure. These druginduced neuroadaptations serve as the molecular basis for relapse vulnerability. In this review, we focus on the role that glutamate signal transduction in the nucleus accumbens plays in addiction-related behaviors. First, we explore the nucleus accumbens, including the cell types and neuronal populations present as well as afferent and efferent connections. Next we discuss rodent models of addiction and assess the viability of these models for testing candidate pharmacotherapies for the prevention of relapse. Then we provide a review of the literature describing how synaptic plasticity in the accumbens is altered after exposure to drugs of abuse and withdrawal and also how pharmacological manipulation of glutamate systems in the accumbens can inhibit drug seeking in the laboratory setting. Finally, we examine results from clinical trials in which pharmacotherapies designed to manipulate glutamate systems have been effective in treating relapse in human patients. Further elucidation of how drugs of abuse alter glutamatergic plasticity within the accumbens will be necessary for the development of new therapeutics for the treatment of addiction across all classes of addictive substances.
AB - The nucleus accumbens is a major input structure of the basal ganglia and integrates information from cortical and limbic structures to mediate goaldirected behaviors. Chronic exposure to several classes of drugs of abuse disrupts plasticity in this region, allowing drug-associated cues to engender a pathologic motivation for drug seeking.Anumber of alterations in glutamatergic transmission occur within the nucleus accumbens after withdrawal from chronic drug exposure. These druginduced neuroadaptations serve as the molecular basis for relapse vulnerability. In this review, we focus on the role that glutamate signal transduction in the nucleus accumbens plays in addiction-related behaviors. First, we explore the nucleus accumbens, including the cell types and neuronal populations present as well as afferent and efferent connections. Next we discuss rodent models of addiction and assess the viability of these models for testing candidate pharmacotherapies for the prevention of relapse. Then we provide a review of the literature describing how synaptic plasticity in the accumbens is altered after exposure to drugs of abuse and withdrawal and also how pharmacological manipulation of glutamate systems in the accumbens can inhibit drug seeking in the laboratory setting. Finally, we examine results from clinical trials in which pharmacotherapies designed to manipulate glutamate systems have been effective in treating relapse in human patients. Further elucidation of how drugs of abuse alter glutamatergic plasticity within the accumbens will be necessary for the development of new therapeutics for the treatment of addiction across all classes of addictive substances.
UR - http://www.scopus.com/inward/record.url?scp=84978997711&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84978997711&partnerID=8YFLogxK
U2 - 10.1124/pr.116.012484
DO - 10.1124/pr.116.012484
M3 - Article
C2 - 27363441
AN - SCOPUS:84978997711
SN - 0031-6997
VL - 68
SP - 816
EP - 871
JO - Pharmacological Reviews
JF - Pharmacological Reviews
IS - 3
ER -